1. Signaling Pathways
  2. Anti-infection
  3. HIV

HIV

Human immunodeficiency virus

HIV (Human immunodeficiency virus) is a lentivirus (a subgroup of retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-175667
    NNRT-IN-12
    Inhibitor
    NNRT-IN-12 (compound 19) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor with an IC50 value of 0.107 μM for WT HIV-1 RT. NNRT-IN-12 shows anti-HIV-1 activity with EC50 value of 14.1, 5.03, 7.64, 27.1 nM for L100I, K103N, Y181C, Y188L mutant HIV-1 strains, respectively. NNRT-IN-12 shows cytotoxicity.
    NNRT-IN-12
  • HY-169064
    HIV-1 inhibitor-75
    Inhibitor
    HIV-1 inhibitor-75 is a human immunodeficiency virus 1 (HIV-1) inhibitor, with an EC50 value ranging from 0.0039 to 0.338 μM. The binding target of HIV-1 inhibitor-75 is reverse transcriptase, with an IC50 value of 0.055 μM. HIV-1 inhibitor-75 shows good in vitro metabolic stability, exhibiting moderate clearance rates and a longer half-life in human plasma and liver microsomes.
    HIV-1 inhibitor-75
  • HY-15601R
    Vesatolimod (Standard)
    Inhibitor
    Vesatolimod (Standard) is the analytical standard of Vesatolimod. This product is intended for research and analytical applications. Vesatolimod (GS-9620) is a potent, selective and orally active agonist of Toll-Like Receptor (TLR7) with an EC50 of 291 nM.
    Vesatolimod (Standard)
  • HY-17040R
    Darunavir (Standard)
    Inhibitor
    Darunavir (Standard) is the analytical standard of Darunavir. This product is intended for research and analytical applications. Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity.
    Darunavir (Standard)
  • HY-178031
    HIV-1-IN-87
    Inhibitor
    HIV-1-IN-87 (Compound 11x) is a dual-site HIV-1 inhibitor targeting the non-nucleoside reverse transcriptase inhibitor binding pocket (NNIBP) and its adjacent site (NNIAS). HIV-1-IN-87 has potent antiviral activities against wild-type and mutant strains (such as L100I, K103N and Y181C) (EC50s: 4.1-150 nM). HIV-1-IN-87 can be used for HIV-1 infections like acquired immune deficiency syndrome (AIDS) research.
    HIV-1-IN-87
  • HY-173427S
    ZK-316
    Inhibitor
    ZK-316 is a potent and broad-spectrum NNRTI inhibitor with an EC50s ranging from 0.99 to 75.1 nM. ZK-316 can be used in the study of HIV.
    ZK-316
  • HY-124477
    Stachybotrylactam
    Inhibitor
    Stachybotrylactam (17) is a phenylspirodrimane isolated from Stachybotrys chartarum with antihyperlipidemic activity. Stachybotrylactam also has antiviral activity.
    Stachybotrylactam
  • HY-N14095
    Curromycin A
    Inhibitor
    Curromycin A has antibacterial activity against Gram-positive bacteria such as Bacillus subtilis. Curromycin A can inhibit the replication of human immunodeficiency virus (HIV), inhibit mouse melanoma B16 and leukemia P388 cells.
    Curromycin A
  • HY-10353AS2
    Raltegravir-d4 potassium
    Inhibitor
    Raltegravir-d4 (potassium) (MK 0518-d4 (potassium)) is deuterium labeled Raltegravir (potassium). Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
    Raltegravir-d<sub>4</sub> potassium
  • HY-126082
    (+)-Carbovir triphosphate
    Inhibitor
    (+)-Carbovir triphosphate is an enantiomer of Carbovir triphosphate (HY-131607). (+)-Carbovir triphosphate is an inhibitor and substrate of HIV reverse transcriptase.
    (+)-Carbovir triphosphate
  • HY-107001
    DPC 961
    DPC 961 (DMP 961) is a non-nucleoside reverse transcriptase inhibitor (NNRTI). DPC 961 is a potent and specific inhibitor of HIV-1 reverse transcriptase, which inhibits the activity of HIV-1 reverse transcriptase in a non-competitive manner, thereby preventing viral replication. DPC 961 can be used for research on AIDS.
    DPC 961
  • HY-14740R
    Elvitegravir (Standard)
    Inhibitor
    Elvitegravir (Standard) is the analytical standard of Elvitegravir. This product is intended for research and analytical applications. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
    Elvitegravir (Standard)
  • HY-10570S1
    Nevirapine-d3
    Inhibitor
    Nevirapine-d3 (BI-RG 587-d3) is the deuterium labeled Nevirapine. Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a Ki of 270 μM.
    Nevirapine-d<sub>3</sub>
  • HY-125183
    BMS-818251
    Inhibitor
    BMS-818251 is a potent, small-molecule inhibitor of HIV-1 entry with an EC50 value of 0.019 nM. BMS-818251 shows >10-fold higher potency than BMS-626529 (HY-15440) on a cross-clade panel of 208-HIV-1 strains. BMS-818251 interacts with gp120 residues from the conserved β20-β21 hairpin to improve potency.
    BMS-818251
  • HY-171574
    3′-Azido-2′,3′-dideoxy-CTP
    Inhibitor
    3′-Azido-2′,3′-dideoxy-CTP (AZddCTP) is a cytidine analog containing a 3-azido group. As a chain terminator, 3′-Azido-2′,3′-dideoxy-CTP can be incorporated into the nascent DNA chain by HIV reverse transcriptase. 3′-Azido-2′,3′-dideoxy-CTP terminates DNA synthesis due to the lack of a 3'-hydroxyl group, thereby inhibiting viral replication. 3′-Azido-2′,3′-dideoxy-CTP has IC50 values of 15.6 μM and 160.8 μM for WT HIV and AZTR HIV. 3′-Azido-2′,3′-dideoxy-CTP has antiviral activity.
    3′-Azido-2′,3′-dideoxy-CTP
  • HY-120157
    Vif-ElonginC interaction inhibitor 1
    Inhibitor
    Vif-ElonginC interaction inhibitor 1 (compound VEC-5) is a potent Vif inhibitor. Vif-ElonginC interaction inhibitor 1 can restrict HIV-1 in Vif-nonpermissive cells. Vif-ElonginC interaction inhibitor 1 can protect A3G, APOBEC3C (A3C), and APOBEC3F (A3F) from Vif-mediated degradation and drastically inhibit Vif function through blocking the interaction between Vif and ElonginC. Vif-ElonginC interaction inhibitor 1 enhances A3G incorporation into HIV-1 virions to reduce viral infectivity.
    Vif-ElonginC interaction inhibitor 1
  • HY-117477
    DPC 963
    Inhibitor
    DPC-963 is an oral active non-nucleoside reverse transcriptase inhibitor with the IC50 of 18 nM. DPC-963 can be used for study of HIV.
    DPC 963
  • HY-172408
    NNRT-IN-6
    Inhibitor
    NNRT-IN-6 (Compound 13a) is the non-nucleoside reverse transcriptase inhibitor (NNRT) for HIV-1 reverse transcriptase (HIV-1 RT) with IC50 of 0.41 μM. NNRT-IN-6 inhibits HIV-1 wildtype and mutant strains L100I, K103N, Y181C, Y188L, E138K, F227L/V106A and RES056 with EC50 of 6.2-250 nM.
    NNRT-IN-6
  • HY-N13712
    Lucidenic lactone
    Inhibitor
    Lucidenic lactone is a terpene compound, is a DNA polymerase inhibitor. Lucidenic lactone inhibits calf DNA polymerase-α, rat DNA polymerase-β, and HIV-1 reverse transcriptase with IC50 values of 42 μM, 99 μM, and 69 μM, respectively.
    Lucidenic lactone
  • HY-78726S2
    Fosamprenavir-13C6
    Inhibitor
    Fosamprenavir-13C6 is the 13C-labeled Fosamprenavir (HY-78726). Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection.
    Fosamprenavir-<sup>13</sup>C<sub>6</sub>
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.